Limits...
Anti-thymocyte globulin could improve the outcome of allogeneic hematopoietic stem cell transplantation in patients with highly aggressive T-cell tumors.

Yang J, Cai Y, Jiang JL, Wan LP, Yan SK, Wang C - Blood Cancer J (2015)

Bottom Line: The early experiment result in our hospital showed that anti-thymocyte globulin (ATG) inhibited the proliferation of lymphoid tumor cells in the T-cell tumors.The maximum cumulative incidence of chronic GvHD was 30%.The most frequent and severe conditioning-related toxicities observed in 8 out of 23 patients were grades III/IV infections during cytopenia.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, Shanghai General Hospital, Shanghai, Jiao Tong University School of Medicine, Shanghai, China.

ABSTRACT
The early experiment result in our hospital showed that anti-thymocyte globulin (ATG) inhibited the proliferation of lymphoid tumor cells in the T-cell tumors. We used the ATG as the part of the conditioning regimen and to evaluate the long-term anti-leukemia effect, the safety and complication in the patients with highly aggressive T-cell lymphomas. Twenty-three patients were enrolled into this study. At the time of transplant, six patients reached first or subsequent complete response, three patients had a partial remission and 14 patients had relapsed or primary refractory disease. The conditioning regimen consisted of ATG, total body irradiation, toposide and cyclophosphamide. The complete remission rate after transplant was 95.7%. At a median follow-up time of 25 months, 16 (69.6%) patients are alive and free from diseases, including nine patients in refractory and progressive disease. Seven patients died after transplant, five from relapse and two from treatment-related complications. The incidence of grades II-IV acute graft-vs-host disease (GvHD) was 39.1%. The maximum cumulative incidence of chronic GvHD was 30%. The most frequent and severe conditioning-related toxicities observed in 8 out of 23 patients were grades III/IV infections during cytopenia. Thus, ATG-based conditioning is a feasible and effective alternative for patients with highly aggressive T-cell tumors.

No MeSH data available.


Related in: MedlinePlus

Probability of relapse.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4526780&req=5

fig2: Probability of relapse.

Mentions: At a median follow-up time of 25 months, a median duration of survive was 25 (2–101) month. Sixteen (69.6%) patients are alive, including nine patients in refractory and progressive disease and seven patients in complete or PR before transplant. (Figure 1). One-year estimate of relapse was 21.7% for all patients (Figure 2).


Anti-thymocyte globulin could improve the outcome of allogeneic hematopoietic stem cell transplantation in patients with highly aggressive T-cell tumors.

Yang J, Cai Y, Jiang JL, Wan LP, Yan SK, Wang C - Blood Cancer J (2015)

Probability of relapse.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4526780&req=5

fig2: Probability of relapse.
Mentions: At a median follow-up time of 25 months, a median duration of survive was 25 (2–101) month. Sixteen (69.6%) patients are alive, including nine patients in refractory and progressive disease and seven patients in complete or PR before transplant. (Figure 1). One-year estimate of relapse was 21.7% for all patients (Figure 2).

Bottom Line: The early experiment result in our hospital showed that anti-thymocyte globulin (ATG) inhibited the proliferation of lymphoid tumor cells in the T-cell tumors.The maximum cumulative incidence of chronic GvHD was 30%.The most frequent and severe conditioning-related toxicities observed in 8 out of 23 patients were grades III/IV infections during cytopenia.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, Shanghai General Hospital, Shanghai, Jiao Tong University School of Medicine, Shanghai, China.

ABSTRACT
The early experiment result in our hospital showed that anti-thymocyte globulin (ATG) inhibited the proliferation of lymphoid tumor cells in the T-cell tumors. We used the ATG as the part of the conditioning regimen and to evaluate the long-term anti-leukemia effect, the safety and complication in the patients with highly aggressive T-cell lymphomas. Twenty-three patients were enrolled into this study. At the time of transplant, six patients reached first or subsequent complete response, three patients had a partial remission and 14 patients had relapsed or primary refractory disease. The conditioning regimen consisted of ATG, total body irradiation, toposide and cyclophosphamide. The complete remission rate after transplant was 95.7%. At a median follow-up time of 25 months, 16 (69.6%) patients are alive and free from diseases, including nine patients in refractory and progressive disease. Seven patients died after transplant, five from relapse and two from treatment-related complications. The incidence of grades II-IV acute graft-vs-host disease (GvHD) was 39.1%. The maximum cumulative incidence of chronic GvHD was 30%. The most frequent and severe conditioning-related toxicities observed in 8 out of 23 patients were grades III/IV infections during cytopenia. Thus, ATG-based conditioning is a feasible and effective alternative for patients with highly aggressive T-cell tumors.

No MeSH data available.


Related in: MedlinePlus